Tempest Therapeutics, Inc.(TPST)Earnings, Financials & Key Ratios
TPST•NASDAQ
$2.02
$56M mkt cap·Price updated May 6, 2026
AboutTempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.Show more
- Revenue$0
- EBITDA-$42M-44.7%
- Net Income-$42M-41.9%
- EPS (Diluted)-1.50+21.5%
- ROE-182.35%-38.7%
- ROIC-507.48%-99.5%
- Debt/Equity0.80+4.1%
- Interest Coverage-31.93-58.7%
TPST Key Insights
Tempest Therapeutics, Inc. (TPST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Shares diluted 81.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TPST Price & Volume
Tempest Therapeutics, Inc. (TPST) stock price & volume — 10-year historical chart
Loading chart...
TPST Growth Metrics
Tempest Therapeutics, Inc. (TPST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1.51%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-323.38%
Return on Capital
10 Years-68.72%
5 Years-77.88%
3 Years-89.43%
Last Year-121.01%
TPST Peer Comparison
Tempest Therapeutics, Inc. (TPST) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 CRIS | 81.2M | 0.62 | -1.06 | -13.43% | -80.29% | -138.81% | 0.30 |
Compare TPST vs Peers
Tempest Therapeutics, Inc. (TPST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TPST Income Statement
Tempest Therapeutics, Inc. (TPST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 653K | 295K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 135.74% | -54.82% | -100% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 5.4M | 28K | 32K | 0 | 815K | 0 | 0 | 0 | 389K | 133K |
| COGS % of Revenue | 827.11% | 9.49% | - | - | - | - | - | - | - | - |
| Gross Profit | -4.75M▲ 0% | 267K▲ 105.6% | -32K▼ 112.0% | -1.05M▼ 3187.5% | -815K▲ 22.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -389K▲ 0% | -133K▲ 0% |
| Gross Margin % | -727.11% | 90.51% | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -140.77% | 105.62% | -111.98% | -3187.5% | 22.53% | 100% | - | - | - | - |
| Operating Expenses | 70.86M | 20.45M | 23.08M | 44.35M | 18.48M | 26.99M | 34.64M | 29.16M | 41.64M | 36.28M |
| OpEx % of Revenue | 10852.07% | 6933.56% | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 49.22M | 5.93M | 8.66M | 16.5M | 4.09M | 9.82M | 12.11M | 11.66M | 13.55M | 13.58M |
| SG&A % of Revenue | 7537.98% | 2009.49% | - | - | - | - | - | - | - | - |
| Research & Development | 21.64M | 14.53M | 14.43M | 27.84M | 14.39M | 17.17M | 22.53M | 17.5M | 28.48M | 22.77M |
| R&D % of Revenue | 3314.09% | 4924.07% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -389K | -67K |
| Operating Income | -81.01M▲ 0% | -20.48M▲ 74.7% | -23.12M▼ 12.9% | -45.4M▼ 96.4% | -19.3M▲ 57.5% | -26.99M▼ 39.8% | -34.64M▼ 28.4% | -29.16M▲ 15.8% | -42.03M▼ 44.1% | -36.42M▲ 0% |
| Operating Margin % | -12406.13% | -6943.05% | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -12.52% | 74.72% | -12.86% | -96.4% | 57.49% | -39.84% | -28.36% | 15.83% | -44.14% | - |
| EBITDA | -78.77M | -20.45M | -23.08M | -44.35M | -18.48M | -26.61M | -34M | -28.78M | -41.64M | -36.17M |
| EBITDA Margin % | -12063.4% | -6933.56% | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -11.4% | 74.03% | -12.86% | -92.11% | 58.32% | -43.98% | -27.77% | 15.37% | -44.69% | -2.76% |
| D&A (Non-Cash Add-back) | 2.24M | 28K | 32K | 1.05M | 815K | 374K | 638K | 381K | 389K | 250K |
| EBIT | -82.06M | -84.3M | -27.04M | -44.57M | -19.21M | -27.02M | -34.09M | -28.04M | -40.53M | -35.6M |
| Net Interest Income | 0 | 0 | 0 | 264K | 90K | -1.28M | -1.07M | -334K | 183K | 363K |
| Interest Income | 0 | 0 | 0 | 264K | 90K | 1.28K | 549K | 1.11M | 1.5M | 817K |
| Interest Expense | 659K | 0 | 134K | 0 | 0 | 1.28M | 1.62M | 1.45M | 1.32M | 454K |
| Other Income/Expense | -6.45M | -64.1M | -4.06M | 831K | 90K | -1.32M | -1.07M | -334K | 183K | 363K |
| Pretax Income | -82.06M▲ 0% | -84.59M▼ 3.1% | -27.18M▲ 67.9% | -44.57M▼ 64.0% | -19.21M▲ 56.9% | -28.3M▼ 47.3% | -35.71M▼ 26.2% | -29.49M▲ 17.4% | -41.84M▼ 41.9% | -36.05M▲ 0% |
| Pretax Margin % | -12566.46% | -28673.22% | - | - | - | - | - | - | - | - |
| Income Tax | 201K | 67K | -169K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.24% | -0.08% | 0.62% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -82.26M▲ 0% | -84.58M▼ 2.8% | -27.19M▲ 67.8% | -44.57M▼ 63.9% | -19.12M▲ 57.1% | -28.3M▼ 48.0% | -35.71M▼ 26.2% | -29.49M▲ 17.4% | -41.84M▼ 41.9% | -36.05M▲ 0% |
| Net Margin % | -12597.24% | -28670.51% | - | - | - | - | - | - | - | - |
| Net Income Growth % | -12.35% | -2.82% | 67.85% | -63.9% | 57.1% | -48.04% | -26.17% | 17.41% | -41.88% | -1.51% |
| Net Income (Continuing) | -82.26M | -84.59M | -27.18M | -44.57M | -19.21M | -28.3M | -35.71M | -29.49M | -41.84M | -36.05M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 12.76M | 2.17M | 1.32M | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -575.73▲ 0% | -72406.33▼ 12476.4% | -263.65▲ 99.6% | -48.77▲ 81.5% | -612.56▼ 1156.0% | -7.80▲ 98.7% | -3.18▲ 59.2% | -1.91▲ 39.9% | -1.50▲ 21.5% | -8.12▲ 0% |
| EPS Growth % | 5.35% | -12476.44% | 99.64% | 81.5% | -1156.02% | 98.73% | 59.23% | 39.94% | 21.47% | -323.38% |
| EPS (Basic) | -575.73 | -72406.33 | -263.65 | -48.77 | -612.56 | -7.80 | -3.18 | -1.91 | -1.50 | - |
| Diluted Shares Outstanding | 142.88K | 1.17K | 103.14K | 913.78K | 31.21K | 291.56K | 888.38K | 15.42M | 27.9M | 4.44M |
| Basic Shares Outstanding | 142.88K | 1.17K | 103.14K | 913.78K | 31.21K | 291K | 888K | 15.42M | 27.9M | 4.44M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TPST Balance Sheet
Tempest Therapeutics, Inc. (TPST) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 116.44M | 19.74M | 83.42M | 71.13M | 19.82M | 68.96M | 32.95M | 40.36M | 31.47M | 8.1M |
| Cash & Short-Term Investments | 114.39M | 67.2M | 77.72M | 63.51M | 18.82M | 51.83M | 31.23M | 39.23M | 30.27M | 7.51M |
| Cash Only | 43.93M | 15.7M | 73.33M | 63.51M | 18.82M | 51.83M | 31.23M | 39.23M | 30.27M | 7.51M |
| Short-Term Investments | 70.46M | 51.5M | 4.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 1.03M | 2.33M | 1.28M | 260K | 15M | 450K | 0 | 0 | 0 |
| Days Sales Outstanding | - | 1.28K | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 2.06M | 1.58M | 3.37M | 6.34M | 59K | 553K | 263K | 96K | 535K | 590K |
| Total Non-Current Assets | 6.1M | 74K | 652K | 3.84M | 3.04M | 4.28M | 13.14M | 11.24M | 10.01M | 9.03M |
| Property, Plant & Equipment | 5.57M | 3.11M | 0 | 3.33M | 2.99M | 4.16M | 12.71M | 10.79M | 9.53M | 8.51M |
| Fixed Asset Turnover | 0.12x | 0.09x | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 504K | 146K | 439K | 0 | 0 | 0 | 0 | 0 | 388K | 0 |
| Other Non-Current Assets | 23K | -3.19M | 213K | 507K | 51K | 111K | 429K | 448K | 97K | 2.07M |
| Total Assets | 122.54M▲ 0% | 19.81M▼ 83.8% | 84.07M▲ 324.4% | 74.97M▼ 10.8% | 22.86M▼ 69.5% | 73.24M▲ 220.3% | 46.09M▼ 37.1% | 51.6M▲ 12.0% | 41.49M▼ 19.6% | 17.13M▲ 0% |
| Asset Turnover | 0.01x | 0.01x | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -11.59% | -83.83% | 324.36% | -10.83% | -69.5% | 220.33% | -37.07% | 11.96% | -19.6% | -138.44% |
| Total Current Liabilities | 13.21M | 4.09M | 9.82M | 12.52M | 3.22M | 20.03M | 7.28M | 9.41M | 14.22M | 3.52M |
| Accounts Payable | 2.18M | 2.24M | 2M | 1.5M | 1.07M | 991K | 1.11M | 845K | 2.45M | 922K |
| Days Payables Outstanding | 147.53 | 29.23K | 22.79K | - | 479.65 | - | - | - | 2.3K | 7.05K |
| Short-Term Debt | 0 | 174K | 189K | 1.96M | 0 | 0 | 0 | 4.29M | 6.35M | 1.15M |
| Deferred Revenue (Current) | 0 | 334K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.03M | 2.29M | 7.63M | 7.02M | 774K | 912K | 1.25M | 1.79M | 0 | 1.46M |
| Current Ratio | 8.82x | 4.82x | 8.50x | 5.68x | 6.15x | 3.44x | 4.53x | 4.29x | 2.21x | 2.21x |
| Quick Ratio | 8.82x | 4.82x | 8.50x | 5.68x | 6.15x | 3.44x | 4.53x | 4.29x | 2.21x | 2.21x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.12M | 738K | 1.14M | 2.58M | 88.43M | 17.09M | 20.7M | 15.42M | 8.14M | 7.26M |
| Long-Term Debt | 0 | 599K | 383K | 168K | 0 | 15.07M | 10.37M | 6.26M | 0 | 7.26M |
| Capital Lease Obligations | 0 | 0 | 0 | 2.4M | 1.73M | 2.03M | 10.33M | 9.16M | 8.14M | 23.56M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.12M | 139K | 752K | 16K | 86.71M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.32M | 4.83M | 10.95M | 15.1M | 91.66M | 37.12M | 27.98M | 24.84M | 22.36M | 10.78M |
| Total Debt | 0 | 773K | 572K | 4.52M | 2.44M | 18.54M | 22.11M | 20.66M | 15.37M | 8.4M |
| Net Debt | -43.93M | -16.85M | -72.76M | -58.99M | -16.38M | -33.29M | -9.12M | -18.57M | -14.9M | 891K |
| Debt / Equity | - | 0.05x | 0.01x | 0.08x | - | 0.51x | 1.22x | 0.77x | 0.80x | 0.80x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.23x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Interest Coverage | -122.93x | - | -172.51x | - | - | -21.05x | -21.41x | -20.12x | -31.93x | -78.41x |
| Total Equity | 108.22M▲ 0% | 14.98M▼ 86.2% | 73.12M▲ 388.0% | 59.87M▼ 18.1% | -68.79M▼ 214.9% | 36.12M▲ 152.5% | 18.11M▼ 49.9% | 26.77M▲ 47.8% | 19.13M▼ 28.5% | 6.35M▲ 0% |
| Equity Growth % | -14.69% | -86.15% | 388.03% | -18.12% | -214.9% | 152.5% | -49.85% | 47.8% | -28.55% | -161.45% |
| Book Value per Share | 757.41 | 12827.91 | 708.99 | 65.52 | -2204.20 | 123.87 | 20.39 | 1.74 | 0.69 | 1.43 |
| Total Shareholders' Equity | 108.22M | 2.23M | 70.95M | 58.55M | -68.79M | 36.12M | 18.11M | 26.77M | 19.13M | 6.35M |
| Common Stock | 36K | 36K | 13K | 18K | 1K | 7K | 11K | 22K | 44K | 4K |
| Retained Earnings | -250.18M | -136.89M | -164.09M | -208.65M | -71.76M | -100.06M | -135.77M | -165.26M | -207.11M | -229.35M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -60K | -19K | 148K | 165K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 12.76M | 2.17M | 1.32M | 0 | 0 | 0 | 0 | 0 | 0 |
TPST Cash Flow Statement
Tempest Therapeutics, Inc. (TPST) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -61.73M | -20.34M | -23.65M | -41.22M | -19.02M | -25.96M | -31.07M | -27.36M | -33.03M | -33.03M |
| Operating CF Margin % | -9453.91% | -6894.92% | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -22.77% | 67.05% | -16.26% | -74.32% | 53.87% | -36.49% | -19.71% | 11.96% | -20.73% | -95.78% |
| Net Income | -82.26M | -84.58M | -27.19M | -44.57M | -19.21M | -28.3M | -35.71M | -29.49M | -41.84M | -36.05M |
| Depreciation & Amortization | 2.24M | 1.65M | 32K | 1.05M | 339K | 374K | 638K | 381K | 389K | 250K |
| Stock-Based Compensation | 9.21M | 6.89M | 1.43M | 0 | 453K | 1.1M | 1.56M | 2.55M | 5.3M | 3.87M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 66.05M | 0 | 4.35M | 470K | 1.48M | 1.57M | 1.88M | 1.51M | 1.2M |
| Working Capital Changes | 4.58M | -1.84M | 1.04M | -2.05M | -1.07M | -613K | 868K | -2.68M | 1.61M | -2.67M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.18M | -1.45M | 320K | -469K | -574K | -209K | 1K | -263K | 1.6M | -775K |
| Cash from Investing | 8.29M | 458K | 1.12M | 3.99M | -6K | -97K | -562K | -170K | -435K | -3K |
| Capital Expenditures | -2.59M | -158K | -36K | -397K | -50K | -135K | -562K | -170K | -435K | -3K |
| CapEx % of Revenue | 396.02% | 53.56% | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | -1.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.45M | 0 | 0 | 44K | 38K | 0 | 0 | 0 | 0 |
| Cash from Financing | 54.15M | -4.46M | 78.55M | 26.94M | 34.6M | 59.06M | 11.4M | 35.6M | 24.5M | 18.44M |
| Debt Issued (Net) | 0 | -4.46M | 6.48M | -202K | 0 | 15M | -4.74M | 0 | -4.4M | -8.63M |
| Equity Issued (Net) | 1000K | 2K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 33.32M | 0 | -401K | 10.64M | 0 | 0 | 307K | 1.87M |
| Net Change in Cash | 706K▲ 0% | -26.31M▼ 3826.2% | 55.71M▲ 311.8% | -9.82M▼ 117.6% | 15.58M▲ 258.6% | 33.01M▲ 111.9% | -20.23M▼ 161.3% | 8.07M▲ 139.9% | -8.96M▼ 211.0% | -14.95M▲ 0% |
| Free Cash Flow | -64.32M▲ 0% | -20.34M▲ 68.4% | -23.68M▼ 16.4% | -41.62M▼ 75.7% | -19.07M▲ 54.2% | -26.09M▼ 36.8% | -31.63M▼ 21.2% | -27.53M▲ 13.0% | -33.46M▼ 21.6% | -33.4M▲ 0% |
| FCF Margin % | -9849.92% | -6896.27% | - | - | - | - | - | - | - | - |
| FCF Growth % | -15.86% | 68.37% | -16.41% | -75.73% | 54.19% | -36.84% | -21.24% | 12.98% | -21.56% | -13.24% |
| FCF per Share | -450.17 | -17417.81 | -229.63 | -45.55 | -610.93 | -89.49 | -35.61 | -1.79 | -1.20 | -1.20 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.24x | 0.87x | 0.92x | 0.99x | 0.92x | 0.87x | 0.93x | 0.79x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 1.54M | 1.25M | 1.18M | 267K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 18K | 191K | 54K | 22K |
TPST Key Ratios
Tempest Therapeutics, Inc. (TPST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -69.99% | -137.3% | -61.73% | -67.02% | - | -78.36% | -131.7% | -131.42% | -182.35% | -568.14% |
| Return on Invested Capital (ROIC) | -82.26% | -47.75% | -8335.1% | -5474.16% | - | - | -439.59% | -254.36% | -507.48% | -507.48% |
| Gross Margin | -727.11% | 90.51% | - | - | - | - | - | - | - | - |
| Net Margin | -12597.24% | -28670.51% | - | - | - | - | - | - | - | - |
| Debt / Equity | - | 0.05x | 0.01x | 0.08x | - | 0.51x | 1.22x | 0.77x | 0.80x | 0.80x |
| Interest Coverage | -122.93x | - | -172.51x | - | - | -21.05x | -21.41x | -20.12x | -31.93x | -78.41x |
| FCF Conversion | 0.75x | 0.24x | 0.87x | 0.92x | 0.99x | 0.92x | 0.87x | 0.93x | 0.79x | 0.93x |
| Revenue Growth | 135.74% | -54.82% | -100% | - | - | - | - | - | - | - |
TPST Frequently Asked Questions
Tempest Therapeutics, Inc. (TPST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tempest Therapeutics, Inc. (TPST) grew revenue by 0.0% over the past year. Growth has been modest.
Tempest Therapeutics, Inc. (TPST) reported a net loss of $36.1M for fiscal year 2024.
Dividend & Returns
Tempest Therapeutics, Inc. (TPST) has a return on equity (ROE) of -182.3%. Negative ROE indicates the company is unprofitable.
Tempest Therapeutics, Inc. (TPST) had negative free cash flow of $33.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More TPST
Tempest Therapeutics, Inc. (TPST) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates